γ-Adducin Stimulates the Thiazide-sensitive NaCl Cotransporter

Henrik Dimke,* Pedro San-Cristobal,* Mark de Graaf,* Jacques W. Lenders,†‡ Jaap Deinum,† Joost G.J. Hoenderop,* and René J.M. Bindels*

*Department of Physiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; †Department of Internal Medicine, Section of Vascular Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; and ‡Department of Medicine III, Carl Gustav Carus University Medical Centre, Dresden, Germany

ABSTRACT

The thiazide-sensitive NaCl cotransporter (NCC) plays a key role in renal salt reabsorption and the determination of systemic BP, but the molecular mechanisms governing the regulation of NCC are not completely understood. Here, through pull-down experiments coupled to mass spectrometry, we found that γ-adducin interacts with the NCC transporter. γ-Adducin colocalized with NCC to the distal convoluted tubule. 22Na uptake experiments in the Xenopus laevis oocyte showed that γ-adducin stimulated NCC activity in a dose-dependent manner, an effect that occurred upstream from With No Lysine (WNK) 4 kinase. The binding site of γ-adducin mapped to the N terminus of NCC and encompassed three previously reported phosphorylation sites. Supporting this site of interaction, competition with the N-terminal domain of NCC abolished the stimulatory effect of γ-adducin on the transporter. γ-Adducin failed to increase NCC activity when these phosphorylation sites were constitutively inactive or active. In addition, γ-adducin bound only to the dephosphorylated N terminus of NCC. Taken together, our observations suggest that γ-adducin dynamically regulates NCC, likely by amending the phosphorylation state, and consequently the activity, of the transporter. These data suggest that γ-adducin may influence BP homeostasis by modulating renal NaCl transport.


Hypertension is a highly prevalent clinical condition and has been estimated to affect as many as 1.56 billion individuals in the year 2025.1 Primary hypertension is a key contributor to cardiovascular complications. As such, hypertension has been estimated to account for a large fraction of strokes and ischemic heart disease on a global scale.2 The National Vital Statistics Report lists heart disease as the primary cause of death, affecting more than 20 million people in the United States alone.3 In addition, elevated BP is a leading cause in the development of chronic renal failure.4 According to the Guytonian model, the kidney plays an essential role in chronic BP maintenance by adjusting blood volume in response to changes in systemic pressure.5 Such modifications are achieved in part by amending the urinary excretion of NaCl.

The Joint National Committee for the detection, evaluation, and treatment of high BP recommends thiazides as the first line treatment of uncomplicated stage I hypertension.6 Thiazides act by blocking NaCl reabsorption in the distal convoluted tubule (DCT), which reclaims 5 to 10% of Na+ from the renal ultrafiltrate.7 It is therefore not surprising

Received June 10, 2010. Accepted October 26, 2010.

Published online ahead of print. Publication date available at www.jasn.org.

H.D. and P.S.-C. contributed equally to this work.

Correspondence: Dr. René Bindels, 286 Physiology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Phone: 31-24-3614211; Fax: 31-24-3614211; E-mail: r.bindels@fysiol.umcn.nl

Copyright © 2011 by the American Society of Nephrology
that disorders disturbing transport processes in this segment affect the renal absorptive capacity for NaCl and thereby influence systemic BP. The thiazide-sensitive NaCl transporter (NCC) is responsible for the majority of inward Na\(^+\) transport in the DCT. In line with this, renal NaCl transport and systemic BP can be changed in Gitelman patients\(^8,9\) and patients with pseudohypoaldosteronism type II.\(^{10,11}\)

A better understanding of the regulation of NaCl transport by NCC may ultimately increase our understanding of how BP is maintained and the etiology of underlying primary hypertension. During the last decade, research within this field has greatly expanded our knowledge about how NaCl transport via NCC is controlled. The cotransporter contains several phosphorylation sites in its N-terminal domain, a feature that is well conserved among several members of the SLC12 family.\(^{12–15}\) Phosphorylation of these residues is critically important for the activation of NCC in response to chloride (Cl\(^−\)) depletion.\(^{12}\) Serine/threonine kinases of the STE20 family (such as the Ste20-related proline-alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1)) as well as the With No Lysine (WNK) kinase family have been shown to play an important role in modulating the phosphorylation state of NCC.\(^{16–19}\) Genetically modified mice strains largely support these observations and solidify the important role of NCC regulation in BP maintenance.\(^{20–25}\)

The aim of this study was to identify novel interactors of NCC that could be involved in modulating its function. Because the N-terminal domain has been shown to play an important role in activation of the transporter, pull-down experiments were performed with this domain of NCC in mouse kidney lysates and subsequently coupled with mass spectrometry. This study describes the identification of \(γ\)-adducin as a novel auxiliary factor interacting with NCC. Adducins were originally identified as heteromeric cytoskeletal proteins implicated in the binding of spectrin to actin.\(^{26}\) \(γ\)-Adducin was selected as an interesting candidate on the basis of the previous involvement of this protein family in primary hypertension in both humans and rats.\(^{27–29}\) Here, we delineated the molecular basis by which \(γ\)-adducin stimulates the activity of NCC.

**RESULTS**

To investigate potential binding partners of the N-terminal domain of NCC, pull-down experiments were performed to screen mouse kidney lysates. The glutathione S-transferase (GST)-coupled N-terminal domain of NCC was used as bait, and the associated proteins were identified by mass spectrometry. The selection of the proteins of interest was based on localization to the distal nephron within the kidney and whether they had previously been involved in hypertension. \(γ\)-Adducin was an interesting candidate that was chosen for further evaluation. The interaction was confirmed by pull-down experiments in human embryonic kidney (HEK) 293 cells transiently transfected with GST-conjugated terminal domains of NCC and hemagglutinin (HA)-tagged \(γ\)-adducin. The resulting cell lysates were incubated with glutathione-coupled Sepharose beads to precipitate GST-bound complexes. Binding was seen by \(γ\)-adducin toward the N-terminal domain of NCC (Figure 1A).

\(γ\)-Adducin has previously been localized to the renal distal tubules,\(^{30}\) whereas actual colocalization with NCC in the DCT was never reported. Immunofluorescence labeling showed that \(γ\)-adducin localizes to the NCC-expressing DCT tubules (Figure 1B). Here, \(γ\)-adducin localized to cytoplasmic and (baso)-lateral domains of the cell. \(γ\)-Adducin was not restricted to the DCT, because expression was also found in the proximal tubule and thick ascending limb as reported previously.\(^{31}\)

To evaluate whether the abundance of \(γ\)-adducin is enriched in the DCT in comparison with other tubules in the renal cortex, DCT fragments were isolated from mice expressing enhanced green fluorescence protein (eGFP) after the parvalbumin promoter.\(^{32}\) The restricted renal expression of this protein to the DCT allowed fluorescence-based sorting of the segment using a complex object parametric analyzer and sorter (COPAS).\(^{33}\) In line with the more ubiquitous expression pattern of the protein as observed by immunohistochemistry, the relative enrichment of \(γ\)-adducin mRNA in the DCT remained unaltered, whereas that for NCC was markedly enriched (Figure 1C).

To estimate the functional effect of \(γ\)-adducin on the transport capacity of NCC, \(^{22}\)Na\(^+\) uptake studies were performed using the *Xenopus laevis* oocyte system. Oocytes injected with cRNA encoding NCC showed a significant thiazide-sensitive \(^{22}\)Na\(^+\) uptake compared with water-injected oocytes. Coinjection with increasing amounts of \(γ\)-adducin cRNA stimulated NCC activity in a dose-dependent manner (Figure 1D). In addition, no difference in the expression level of HA-NCC could be detected between oocytes injected without or with increasing concentrations of HA-\(γ\)-adducin in the presence of HA-NCC. A dose-dependent increase was observed in the abundance of the HA-tagged \(γ\)-adducin.

To evaluate whether \(γ\)-adducin plays a role in maintaining basal NCC-dependent \(^{22}\)Na\(^+\) transport in the oocyte, small interference RNA (siRNA) against endogenous *X. laevis* \(γ\)-adducin was injected in oocytes preinjected with NCC. When siRNA against \(γ\)-adducin was injected, a significant decrease in thiazide-sensitive \(^{22}\)Na\(^+\) uptake was observed (Supplemental Figure 1A). Because the related family member \(α\)-adducin does not affect NCC-dependent transport (Supplemental Figure 1B), the oocytes were injected with siRNA against \(α\)-adducin as a negative control. Injection of \(α\)-adducin siRNA did not significantly affect the activity of NCC.

To investigate whether \(γ\)-adducin affects NCC activity via the same signaling cascade as WNK4, the effect of WNK4 on \(γ\)-adducin-stimulated Na\(^+\) transport was evaluated. WNK4 has been shown to reduce NCC activity by directing the protein to the lysosomal compartment.\(^{34,35}\) In line with this, WNK4 was able to inhibit NCC-dependent \(^{22}\)Na\(^+\) uptake (Figure 2A). Importantly, the stimulatory effect of \(γ\)-adducin was also ob-
served in the presence of WNK4 (Figure 2A). Moreover, injections of increasing concentrations of γ-adducin reverted the inhibitory effect of WNK4 on NCC-mediated \( ^{22}\text{Na}^+ \) uptake (Figure 2B). Furthermore, the effect of γ-adducin abrogated the WNK4-dependent reduction in NCC activity, because the stimulatory effect of γ-adducin was still present when increasing amounts of WNK4 cRNA were injected (Figure 2C).

The stimulatory effect of γ-adducin on NCC may be explained by increased trafficking of the transporter to the plasma membrane or by changes in the intrinsic activity of the transporter. To evaluate whether the membrane abundance of NCC increases in the presence of γ-adducin, cell surface expression of eGFP-NCC was determined by confocal laser scanning microscopy. The intensity of the eGFP signal at the plasma membrane as well as the \( ^{22}\text{Na}^+ \) uptake rates correlated dose-dependently with the amount of injected eGFP-NCC cRNA (Figure 3, A and B). Thus, this method was used to determine semiquantitatively the presence of NCC at the plasma membrane. Coinjection of γ-adducin significantly increased eGFP-NCC-dependent \( ^{22}\text{Na}^+ \) uptake, whereas the auxiliary protein γ-adducin did not significantly affect the plasma membrane expression of eGFP-NCC (Figure 3, C and D).

To delineate whether γ-adducin affects NCC function by its interaction with the N terminus of NCC, competition assays were performed in which NCC and γ-adducin were coinjected together with increasing amounts of the N terminus of NCC. During these conditions, injection of the NCC N terminus abolished the stimulatory effect of γ-adducin on NCC activity (Figure 4A).

The binding site of γ-adducin in the N terminus of NCC was subsequently mapped by pull-down analysis. For determination of the binding site, a series of fragments from the N-terminal domain of NCC were generated as depicted in Figure 4B, with residues 1 to 135 representing the full-length N-tail. All of the N-terminal fragments were fused to GST to allow precipitation using

---

**Figure 1.** γ-Adducin binds the N terminus of NCC and stimulates the activity of the cotransporter. (A) GST pull-down assay in HEK293 cells transiently transfected with either the GST-tagged N or C terminus of NCC or GST alone, all in combination with γ-adducin, was used to evaluate binding of γ-adducin to NCC. CP denotes coprecipitate, and IB represents the protein immunoblotted against. (B) γ-Adducin localizes with NCC to the DCT. Representative immunohistochemical images are shown as obtained by confocal laser microscopy. The sections were incubated with specific antibodies against NCC and γ-adducin and stained using Alexa-conjugated secondary antibodies. (C) γ-Adducin mRNA is expressed in the DCT as well as in other nephron segments. Semiquantitative real-time PCR was used to determine the abundance of NCC and γ-adducin mRNA extracted from fluorescently sorted DCT tubules and the kidney cortex (CTX). (D) Effect of γ-adducin upon NCC function. γ-Adducin stimulated NCC activity in a dose-dependent manner. \( ^{22}\text{Na}^+ \) uptakes in \( X. \) laevis oocytes microinjected with water, 5 ng of HA-tagged human NCC cRNA alone, or in combination with increasing amounts of HA-tagged γ-adducin cRNA (n = 8). The experiment was performed in the absence (open bars) or presence (closed bars) of 0.1 mM thiazide. The data are presented as the means ± SEM. *P < 0.05 is statistically significant as compared with NCC-injected oocytes. Western blots were used to quantify the expression of NCC and γ-adducin in groups of oocytes injected as described above. The data are presented as the means ± SEM.
glutathione-coupled Sepharose beads. N-terminal deletion fragments of NCC were expressed transiently in HEK293 cells together with /H9253-adducin. GST pull-down experiments revealed that /H9253-adducin only binds the N terminus when the 1 to 80 fragment is present, albeit at a lower affinity than to the full length N-tail (Figure 4, C and D).

Because the part of the N-terminal domain of NCC that binds /H9253-adducin encompasses the three phosphorylation sites of NCC (Thr55, Thr60, and Ser73 in human NCC), which previously have been shown necessary for activation of the protein in response to Cl− depletion,12 the role of /H9253-adducin on the phosphorylation of NCC was evaluated. /H9253-adducin was coinjected with triple phosphorylation site NCC mutants (converted to alanines (A) or aspartates (D) to mimic either the constitutively inactive or active sites, respectively), and 22Na+ uptakes were performed. The stimulatory effect of /H9253-adducin on NCC-mediated Na+ transport was lost when the three phosphorylation sites were converted into constitutively active sites (D) (Figure 4E), suggesting an important role of /H9253-adducin in modulating the phosphorylation of NCC. Similarly, when the N-terminal phosphorylation sites were converted to inactive phosphorylation sites (A), NCC-dependent 22Na+ transport dropped markedly in line with previously published data (Figure 4E).12 Also in this experimental setting, when the phosphorylation sites were made constitutively inactive, /H9253-adducin had no effect on NCC-mediated 22Na+ transport.

These data suggest that the stimulatory effect of /H9253-adducin is critically dependent on the phosphorylation sites in the N-terminal domain of NCC. To further elucidate the relationship between /H9253-adducin and NCC, pull-down experiments were performed to determine whether binding of /H9253-adducin to the N-tail of NCC was dependent on the phosphorylation status of this domain. Thus, GST pull-downs were performed using the N terminus of NCC as well as the N-terminal constitutively inactive or active phosphorylation forms (Figure 4F). Binding of /H9253-adducin was found to the N terminus of wild-type NCC and the constitutively inactive form, whereas no binding was observed to the constitutively active phosphorylation form of NCC.

**DISCUSSION**

NCC is of crucial importance for the reabsorption of NaCl by the kidney, thus influencing arterial pressure. Here, we report the identification of /H9253-adducin, a novel auxiliary protein interacting with the N-terminal domain of NCC. Our study is the first to delineate the stimulatory action of /H9253-adducin on the thiazide-sensitive NaCl cotransporter and highlights that the effect of /H9253-adducin is critically dependent on the phosphorylation status of NCC. These observations are based on the following data: (1) the identified protein /H9253-adducin binds strongly to the N-terminal domain of NCC and markedly stimulates the activity of the transporter; (2) the stimulatory actions of /H9253-adducin occur in the regulatory cascade before the WNK4-dependent lysosomal shuttling of NCC; (3) competition with increasing amounts of the N-terminal part of NCC completely reverts the stimulatory action of /H9253-adducin on thiazide-sensitive 22Na+ transport; (4) the /H9253-adducin-binding site is mapped to the part of the N-ter-
tein exhibits homology with the previously identified in the presence or absence of 10 ng of H9253 panel) of X. laevis oocytes injected with 1 to 10 ng of GFP-NCC cRNA (corresponding to Thr 55 and Thr60 phospho-form of human NCC), is found exclusively at the membrane as evaluated by electron microscopy.38 Similarly to NCC in oocytes, the NCC forms lacking phosphorylatable sites in the N terminus do not exhibit increased $^{22}$Na$^+$ uptake when the transporter is incubated at hypotonic low Cl$^-$ conditions, which noticeably increases its phosphorylation level, NCC increases its activity, again independent of trafficking to the oocyte membrane. In line with this finding is the observation that the Thr$^{556}$- and Thr$^{557}$-phosphorylated form of the related family member, the rat furosemide-sensitive Na$^+$, K$^+$, 2Cl$^-$ cotransporter (NKCC2) (corresponding to Thr$^{559}$ and Thr$^{560}$ phospho-form of human NCC), is found exclusively at the membrane as evaluated by electron microscopy.38 Similarly to NCC in oocytes, when the phosphorylation level of NKCC2 is increased by growth hormone, no change in trafficking of the transporter can be observed. Consequently, the γ-adducin-stimulated NCC activity needs to be explained by an intrinsic change in transporter activity, because the amount of trans-

Figure 3. The effect of γ-adducin occurs independent of NCC trafficking to the oocyte membrane. (A) $^{22}$Na$^+$ uptakes in X. laevis oocytes injected with 1 to 10 ng of GFP-NCC cRNA (n = 4). (B) Corresponding GFP fluorescence at the membrane of oocytes injected with 1 to 10 ng of GFP-NCC cRNA (n = 4). (C) Effect of thiazide-sensitive $^{22}$Na$^+$ uptake (n = 4) (left panel) and quantification of the GFP fluorescence in the membrane (n = 4) (right panel) of X. laevis oocytes injected with 10 ng of GFP-NCC cRNA in the presence or absence of 10 ng of γ-adducin cRNA. (D) Representative images of GFP fluorescence at the oocyte membrane after injection with increasing amounts of GFP-NCC cRNA as well as the group coinjected with 10 ng of γ-adducin cRNA using confocal laser scanning microscopy. *P < 0.05 is statistically significant.

minal domain of NCC that encompasses three phosphorylation sites that previously have been shown to affect the activity of the cotransporter; (5) NCC forms lacking phosphorylatable sites in the N terminus do not exhibit increased $^{22}$Na$^+$ transport rates when coinjected with γ-adducin; and (6) γ-adducin dissociates from NCC when the phospho-residues are converted to aspartates, mimicking a constitutively active phosphorylated state.

γ-Adducin was originally cloned from rat kidney.36 The protein exhibits homology with the previously identified α- and β-adducin family members. Adducins are heteromeric membrane skeletal proteins originally implicated in spectrin-actin binding.36 The adducins form heteromeric proteins composed of either α- and β-subunits or α- and γ-subunits. Because the β-subunit has a restricted expression and is primarily found in brain and hemopoetic tissues, it has been suggested that the α- and γ-subunits function as heteromers in tissues where the β-subunit is absent.34 It is interesting to note that although γ-adducin localizes to the DCT with NCC, α-adducin, which is also expressed in the kidney, seems absent from the distal tubules, although expression of both reappears in the collecting duct.31 This may suggest that γ-adducin has a unique function in DCT, where it could function as a homomer. In line with this is our observation that α-adducin fails to stimulate the activity of NCC in the oocyte system. The adducin gene family has previously been implicated in arterial hypertension. A G460W polymorphism in the α-adducin gene showed linkage to primary hypertension in certain patient groups.37 One intrinsic single nucleotide polymorphism has currently been described in the γ-adducin gene (A/G; rs3731566), which correlates with peripheral and central pulse pressures (because of increases in systolic pressure), changes in the urinary Na$^+$/K$^+$ ratio, and urinary aldosterone excretion, but only in individuals that also harbor the G460W polymorphism in α-adducin.37 These observations suggest that γ-adducin can affect BP; however, to be visible clinically, arterial pressure needs to be perturbed by the G460W polymorphism in α-adducin.

γ-Adducin is able to revert the inhibitory effect of WNK4 on NCC. Consequently, our observation implies that γ-adducin protects against the inhibitory actions of WNK4, either by affecting processes occurring before lysosomal removal of the protein or by directly blocking the WNK4-dependent inhibitory action on NCC. Because no changes in the membrane localization of NCC were observed after coinjection of γ-adducin, one may conclude that γ-adducin controls processes preceding lysosomal shuttling of NCC. The functional effect of phosphorylation of the thiazide-sensitive NCC transporter has not been fully delineated. Previous studies have reported that when the N-terminal phosphorylation sites in NCC are converted to alanines mimicking inactive phosphorylation sites, the activity of the transporter is markedly decreased. This occurs even although the membrane abundance remains unaffected, suggesting that the intrinsic activity is inhibited.12 Similarly, when the transporter is incubated at hypotonic low Cl$^-$ conditions, which noticeably increases its phosphorylation level, NCC increases its activity, again independent of trafficking to the oocyte membrane. In line with this finding is the observation that the Thr$^{556}$- and Thr$^{557}$-phosphorylated form of the related family member, the rat furosemide-sensitive Na$^+$, K$^+$, 2Cl$^-$ cotransporter (NKCC2) (corresponding to Thr$^{559}$ and Thr$^{560}$ phospho-form of human NCC), is found exclusively at the membrane as evaluated by electron microscopy.38 Similarly to NCC in oocytes, when the phosphorylation level of NKCC2 is increased by growth hormone, no change in trafficking of the transporter can be observed.12 Consequently, the γ-adducin-stimulated NCC activity needs to be explained by an intrinsic change in transporter activity, because the amount of trans-

porters in the membrane remains unchanged. Such changes could ensue, for instance, if affinity constants for Na\(^+\) or Cl\(^-\) shift, to such a degree that the maximal velocity is altered. Thus, the data obtained in our study as well as the previous literature strongly imply a link between the phosphorylation state and the intrinsic activity of the transporter.

We found that the effect of \(\gamma\)-adducin is entirely dependent on the phosphorylation sites of NCC. The sequence of

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure4}
\caption{Phosphorylation of the N terminus of NCC is essential for the stimulatory effect of \(\gamma\)-adducin. (A) The ability of the NCC N-terminal domain to inhibit \(\gamma\)-adducin-stimulated transport of the cotransporter as evaluated by \(^{22}\text{Na}\) uptakes. The oocytes were coinjected with 5 ng of NCC cRNA, 10 ng of \(\gamma\)-adducin cRNA, and increasing amounts of the N-terminal domain of NCC (from 2.5 to 10 ng) \((n = 3)\). \(^*\) \(P < 0.05\) is statistically significant from all other groups. (B) Schematic drawing representing the GST fusion proteins containing different portions of the N-terminal tail of NCC. These were generated to map the binding site of \(\gamma\)-adducin to NCC. Black domains represent the N-terminal phosphorylation sites, whereas gray denotes the SPAK binding site. (C) GST pull-down assay in HEK293 cells. Deletion fragments of the NCC N-terminal domain (amino acids 1 to 135, 1 to 80, and 1 to 40) coupled to GST were generated to determine the HA-\(\gamma\)-adducin-binding site within the cotransporter. (D) GST pull-down assay repeated, but the N terminus was truncated from the opposite end (amino acids 1 to 135, 40 to 135, 80 to 135, and 112 to 135). Note that \(\gamma\)-adducin binds only in the presence of the full-length terminus or the 1 to 80 fragment. (E) The effect of \(\gamma\)-adducin requires phosphorylatable NCC sites. \(^{22}\text{Na}\) uptakes were performed in oocytes injected with 5 ng of NCC cRNA, 5 ng of constitutively inactive (NCC TM(A); T55A, T60A, S73A), or 5 ng of the constitutively active (NCC TM(D); T55D, T60D, S73D) NCC phosopho-mutants, in the presence or absence of 10 ng of \(\gamma\)-adducin cRNA \((n = 2)\). (F) GST pull-down assay in HEK293 cells. Coprecipitation of HA-tagged \(\gamma\)-adducin with the native GST-N terminus and the GST-N terminus containing constitutively inactive and active phosphorylation sites. CP denotes coprecipitate, IB indicates the protein that was immunoblotted, and NCC WT indicates wild-type NCC. The \(^{22}\text{Na}\) uptake experiments were performed in the presence (closed bars) or absence (open bars) of 0.1 mM thiazide. \(^*\) \(P < 0.05\) is statistically significant from NCC-injected oocytes.
\end{figure}
γ-adducin does not suggest that the protein is a kinase. Furthermore, there is no experimental evidence showing that γ-adducin or other members of the family possess kinase activity. The most likely explanation is that γ-adducin associates with kinases involved in the phosphorylation of the transporter, thereby anchoring them to the dephosphorylated N terminus of the transporter. The STE20 family of kinases, comprising members such as SPAK and OSR1, has been shown to increase the phosphorylation state of NCC in vitro and in vivo.\textsuperscript{16,24} In addition, WNK1, via SPAK and OSR1, has previously been shown to be responsible for increasing the transport activity and phosphorylation level of NCC during hypotonic Cl\textsuperscript{−}–depleted conditions.\textsuperscript{16} Moreover, WNK4 plays an important role in stimulating the NCC phosphorylation via SPAK and OSR1 in response to angiotensin II–mediated receptor activation.\textsuperscript{39} The phosphorylation state of NCC is also markedly enhanced by dietary NaCl restriction, an effect that appears aldosterone-dependent and is lost in transgenic animals with a pseudohypoaldosteronism type II mutation in WNK4.\textsuperscript{40} Consequently, phosphorylation of the N-terminal domain in NCC seems to be a common final pathway by which several stimuli converge to regulate the activity of the transporter. Here, we report that γ-adducin may function as an important component in the phosphorylation cascade of NCC.

As can be observed from the immunohistochemical stainings, the γ-adducin protein colocalizes with the NCC cotransporter to the DCT. γ-Adducin is confined primarily to cytoplasmic domains oriented near the basolateral region of the cell, whereas NCC is found in apical domains of the cell. However, the adducins have previously been shown to play multiple roles within the cell, such as promoting cytoskeletal spectrin–actin binding,\textsuperscript{26} and larger fractions of the γ-adducin protein may be associated with those kind of structures, thus explaining the localization of the majority of protein. It is also unclear how the cytoskeleton is organized in the DCT after periodate/lysine paraformaldehyde (PLP) fixation and freezing. Therefore, what is observed in the kidney section may not exactly mirror the subcellular localization of this protein in the native DCT cell. In addition, γ-adducin is a cytoplasmic protein that may show a gradient in its distribution, where the large majority of the protein is localized to cytoskeletal structures, compatible with its multiple functions within the cell. Thus, only a minor fraction could be present at the apical plasma membrane. In primary renal proximal tubule epithelial cells, γ-adducin is found in basolateral domains of the cell, whereas protein kinase C–dependent phosphorylation of the protein induces its redistribution toward the cytoplasm.\textsuperscript{30} The potential regulation of γ-adducin in the DCT as well as its subcellular distribution deserves further scrutiny, particularly after activation of intracellular signaling cascades that has been shown to affect the phosphorylation of NCC.

On the basis of the data generated in our study, we postulate that γ-adducin stimulates NCC activity by anchoring a kinase, likely SPAK or OSR1 to the dephosphorylated transporter. Subsequently, the kinase increases the phosphorylation level of NCC, thereby stimulating the activity of the transporter. After the kinase–mediated phosphorylation event, γ-adducin dissociates from NCC and may also facilitate the release of the associated kinase. Dephosphorylation of the transporter reduces the activity of NCC to its basal state. However, this event also allows for the binding of γ-adducin to the N terminus again, and the cycle can be repeated. Thus, these speculations infer a dynamic model in which γ-adducin binding and dissociation to NCC is directly correlated with the dephosphorylation and phosphorylation of the transporter, respectively.

In this study, the influence of γ-adducin on NCC–dependent NaCl transport was evaluated using the X. laevis oocyte expression system. This in vitro system provides a powerful approach to directly study NCC function at the cellular and molecular level. In general, the results obtained in the oocyte expression system pertaining to the function and regulation of NCC mirror quite accurately those reported in vivo.\textsuperscript{21,24,41} Despite the substantial success of the oocyte expression system, there are several limitations that should be noted. Obviously, the oocyte system represents a simplification of the in vivo situation and does not adequately reflect the complexity of the DCT cell, much less the kidney. In addition, several cofactors that may be necessary for the appropriate regulation of NCC could be absent from the oocyte. Thus, by recognizing these limitations in relation to the data obtained in this study, we can only extrapolate that the effect of γ-adducin on NCC function is likely to occur in vivo. However, further studies in appropriate animal models are needed to definitively support this conclusion.

In summary, we identified γ-adducin as a regulator of NCC in oocytes and showed that the stimulatory action of γ-adducin is intimately linked with the N-terminal phosphorylation sites in the cotransporter. On the basis of our data, γ-adducin may contribute importantly to the regulation of NCC and hence BP maintenance. Our findings will aid in the understanding of the complex cascade regulating NCC activity. Importantly, the observations made in our study may help elucidate the molecular events underlying the formation of primary hypertension.

**CONCISE METHODS**

**Constructs**

HA-tagged human NCC in pT7Ts has been previously described.\textsuperscript{42} The human γ-adducin clone was obtained from Imclone Systems (New York, NY), subcloned into a pCI-Neo-IREs-GFP vector, and further subcloned into pT7Ts. GST-conjugated N- and C-terminal fragments of NCC were subcloned by PCR to pGEX-6p-2 for *Escherichia Coli* protein production and further subcloned into pEBG vectors for expression of GST-fused proteins in HEK293 cells. GST-fused proteins containing different portions of the N-
terminal domain of NCC were constructed according to the schematic drawing in Figure 4B. These constructs inserted in pEBG vectors were generated either by PCR subcloning or truncated by stop codons using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). In addition, the N-terminal domain of NCC (amino acids 1 to 135) for the competition assay was generated by insertion of a stop codon by site-directed mutagenesis in the full-length NCC in pT7Ts. The triple phospho sites (Thr55, Thr60, and Ser73) in NCC mimicking constitutively inactive (converted to alanines) or active (converted to aspartates) phosphoproteins were generated by site-directed mutagenesis in pT7Ts vectors. Similarly, the N termini with modified phosphorylation sites were further subcloned by PCR into pEBG for GST pull-down analysis. A Myc tag was inserted in front of WNK4 by site-directed mutagenesis, and the complete insert was placed into a pT7Ts vector using the gateway system (Invitrogen, Breda, The Netherlands). For generation of eGFP-NCC in pT7Ts, human NCC was subcloned by PCR from human NCC pT7Ts and constructed behind eGFP in a pCB7 vector. The complete insert was thereafter subcloned into pT7Ts. Human α-adducin (Imclone Systems) was subcloned into a pT7Ts vector. All of the inserts were verified by direct sequencing.

**GST Pull-down and Mass Spectrometry**
The intracellular N- and C-terminal domains of NCC coupled to GST were produced in E. coli BL21 cells. The bacteria were lysed, and the GST-NCC terminal fusion domains were purified on glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech). C57BL/6 mice were killed under 1.5% vol/vol isofluorane anesthesia (Nicholas Piramal Limited, London, UK), and the kidneys were homogenized in lysis buffer (20 mM Tris/HCl, 140 mM NaCl, 1 mM CaCl2, 0.2% (vol/vol) methanol, and the kidneys were homogenized in digestion solution containing 40% sucrose, and 1 mg/ml hyaluronidase [#H3884; Sigma Aldrich, Zwijndrecht, The Netherlands] in KREBS [145 mM NaCl, 10 mM HEPES, 5 mM KCl, 1 mM NaH2PO4, 2.5 mM CaCl2, 1.8 mM MgSO4, 5 mM glucose, pH 7.3]). The animal ethics board of Radboud University Nijmegen approved all of the experimental procedures. The kidney cortex was finely minced and incubated in digestion solution for 22 minutes at 37°C, subsequently sieved through a series of meshes, and finally collected on a 40-μm filter. Fluorescently labeled DCT tubules were isolated from transgenic animals, using a COPAS sorter (Union Biometrica, Somerville, MA) as described in detail previously.33 The GFP-positive fraction consists of DCT fragments. The remainder was saved and denoted whole kidney tubules. Tubule RNA was extracted using TRIzol Total RNA Isolation Reagent (Life Technologies BRL, Breda, The Netherlands) and processed into cDNA. The cDNA was mixed with Power SYBR® green PCR Mastermix (Applied Biosystems, Foster City, CA) and exon overlapping primers against γ-adducin (5′-CACATTCACACCCCTTGGCCAC-3′; 5′-CTTGGTAGCTCATAG-TAGGGCAG-3′), NCC (5′-CTTCGGGCACCTGGCATTTCTG-3′; 5′-GATGGCAAGGTAGGAGATTG-3′), and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (5′-AACATAATGGGGTGTA-3′; 5′-GGTTCCACACCCATCACAA-3′).

**In Vitro cRNA Translation**

pT7Ts plasmid vectors were linearized by restriction digestion at the SstI-end of the insert. The plasmids were transcribed in vitro using the mMESSAGE mMACHINE® T7 Kit (Ambion, Austin, TX) to generate cRNA. The integrity of the product was confirmed on 1% (wt/vol) formaldehyde gels. RNA concentrations were determined spectrophotometrically at 260 nm. The cRNA aliquots were stored at −80°C.

**Evaluation of NCC Function**
All of the animal experiments described below received the approval from the animal ethics board of Radboud University Nijmegen. Isolation and 22Na+ uptakes in oocytes were done as described previously,43 with minor modifications. Briefly, X. laevis oocytes were surgically collected after decapitation, manually separated, and incubated in collagenase A (1 mg/ml). Incubations were done in Ca2+-free ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES/NaOH, pH 7.4, 50 mg/L gentamicin). The following day, stage V and VI oocytes were selected and injected with the appropriate cRNAs in a final volume of 50 nl/oocyte. The oocytes were subsequently incubated in Ca2+-containing ND96 including 1.8 mM CaCl2 for 2 to 3 days at 16°C. 16 hours before the uptake, the oocytes were placed in Cl−-depleted medium (96 mM sodium isethionate, 2 mM potassium gluconate, 1.8 mM calcium gluconate, 1 mM Mg(NO3)2, 5 mM HEPES/NaOH, pH 7.4, 50 mg/dL gentamicin, approximately 200 mOsm). Before the uptake, the oocytes were pre-incubated in 1 mM ouabain, 0.1 mM amiloride, and 0.1 mM bumetanide in the absence or presence of 0.1 mM thiazide in Cl−-depleted medium. 22Na+ uptake (1 μCi 22Na+/ml; Perkin Elmer) was done in K+-free isotonic uptake buffer (40 mM NaCl, 56 mM N-methyl-D-
glutamine (NMDG)-Cl, 1.8 mM CaCl₂, 1 mM MgCl₂, 5 mM HEPES/NaOH, pH 7.4) for 1 hour. The oocytes were washed five times at the end of the ²²Na⁺ incubation with ice-cold uptake medium, transferred to scintillation vials, and lysed in 10% (w/v) sodium dodecyl sulfate. Radioactivity was counted in a liquid scintillation counter.

### Evaluation of Total Expression of NCC and γ-Adducin in the Oocyte

HA-NCC was detected in total membrane isolates, whereas HA-γ-adducin was detected in the remaining cytosolic fraction. As described in detail previously, membrane preparations and total lysates were prepared, blotted onto membranes, and detected using an enhanced chemiluminescence system (Pierce, Rockford, IL).

### Quantification of eGFP-NCC in the Oocyte Membrane

The oocytes were injected with 1, 5, or 10 ng of eGFP-NCC cRNA as well as 10 ng of eGFP-NCC cRNA in the presence of 10 ng of γ-adducin cRNA. Images were acquired on an Olympus FV1000 laser-scanning microscope (Center Valley, PA, USA) using a 20× objective. Background subtraction and semiquantitative determination of eGFP-NCC abundance at the plasma membrane was done using Image J (National Institutes of Health, Bethesda, MD).

### siRNA against X. laevis γ-Adducin

To confirm endogenous expression of γ-adducin in X. laevis oocytes, primers designed against γ-adducin in Xenopus tropicalis were used to amplify a fragment by RT-PCR (TaKaRa Taq™, Shiga, Japan) from oocyte cDNA. The fragment was extracted from the gel and sequenced. Sequence similarity was identical to the previously published mRNA of hypothetical protein LOC432146 from X. laevis. siRNA was designed using double-stranded oligo-probes against the following sequence of endogenous X. laevis γ-adducin, 5′-AATGACCCCGGCTACATCCGC-3′. Double-stranded probes were also designed against X. laevis α-adducin 5′-AATGGTGAGTCGATGTAG-3′, on the basis of the previously published sequence (NM_001087641). Oocytes were injected with 5 ng of HA-NCC siRNA as described above. siRNAs were injected 24 hours before the uptake.

### Immunohistochemistry

Kidneys from C57BL/6 mice were immersion fixated in 1% (w/v) PLP fixative. 10-μm cryosections were prepared and costained with anti-γ-adducin antibodies (1:25, rabbit, H-60; Santa Cruz Biotechnology, Santa Cruz, CA) and NCC (1:100, guinea pig; generously provided by Jan Loffing, Switzerland). The images were acquired on an Olympus FV1000 laser-scanning microscope (Center Valley, PA).

### Statistical Analysis

All of the results obtained in oocytes were the averages of two to eight independent experiments, each containing a minimum of ten oocytes per group. Overall statistics between groups was determined by one-way ANOVA. In case of significance, multiple comparisons between groups were performed by Bonferroni post hoc tests. The values are presented as the means ± SEM. P < 0.05 is considered statistically significant.

### ACKNOWLEDGMENTS

The authors are grateful to our colleagues Jan Janssen, Henk Arnts, Femke van Zeeland, Jolein Gloorich, AnneMiete van der Kemp, Huib Croes, and Ron Engels for technical assistance and helpful suggestions. We greatly appreciate the support of Dr. Hannah Monyer, Universitätsklinikum Heidelberg, Germany, for kindly donating the transgenic mouse line B-Pv-E. This study was supported financially by the Dutch Kidney Foundation (C05.4106), the Netherlands Organization for Scientific Research (ZonMW 9120.6110; ALW 700.55.302), and a EURYI award from the European Science Foundation to J.H.

### DISCLOSURES

None.

### REFERENCES

13. Darman RB, Forbush B: A regulatory locus of phosphorylation in the N


11. Vitari AC, Deak M, Morrice NA, Alessi DR: The WNK1 and WNK4 protein kinases that are mutated in Gordon’s hypertension syndrome phosphate and activate SPAK and OSR1 protein kinases. Biochem J 391: 17–24, 2005


